Luciana Pereira Rangel

Instituição:

Universidade Federal do Rio de Janeiro

Centro:

Centro de Ciências da Saúde

Unidade:

Faculdade de Farmácia

Departamento:

Departamento de Análise Clínica e Toxicologica

e-mail:

lprangel@pharma.ufrj.br

Linkedin:

Google Scholar:

https://scholar.google.com.br/citations?user=rgPBfTsAAAAJ&hl=pt-BR

ORCID:

não disponível no Lattes

Formação:

  • Universidade Federal do Rio de Janeiro

    | Pós-Doutorado | 2013 - 2013

  • Universidade Federal do Rio de Janeiro

    | Pós-Doutorado | 2009 - 2013

  • Universidade Federal do Rio de Janeiro

    Ciências (Microbiologia) | Doutorado | 2005 - 2009

  • Universidade Federal do Rio de Janeiro

    Ciências (Microbiologia) | Mestrado | 2003 - 2005

  • Universidade Federal do Rio de Janeiro

    Farmácia Habilitação em Análises Clínicas | Graduação | 1998 - 2002
Laboratórios:
Nuvens de Palavras:
Artigos:

(96.97% artigos com DOI)

Titulo DOI Ano
A further pocket or conformational plasticity by mapping COX-1 catalytic site through modified-mofezolac structure-inhibitory activity relationships and their antiplatelet behavior 10.1016/j.ejmech.2024.116135 2024
Naphthoquinone-Quinolone Hybrids with Antitumor Effects on Breast Cancer Cell Lines-From the Synthesis to 3D-Cell Culture Effects 10.3390/ijms25126490 2024
PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma 10.3389/fmolb.2023.1165132 2023
In vivo evaluation of time-dependent antithrombotic effect of rivaroxaban-loaded poly(lactic-co-glycolic acid)/sodium lauryl sulfate or didodecyl dimethylammonium bromide nanoparticles in Wistar rats 10.1016/j.ejpb.2023.07.016 2023
Anticancer Therapeutic Strategies Targeting p53 Aggregation 10.3390/ijms231911023 2022
Aminoquinolones and Their Benzoquinone Dimer Hybrids as Modulators of Prion Protein Conversion 10.3390/molecules27227935 2022
Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues 10.3390/molecules25040893 2020
Recent Synthetic Approaches towards Small Molecule Reactivators of p53 10.3390/biom10040635 2020
Bioactive Compounds and Metabolites from Grapes and Red Wine in Breast Cancer Chemoprevention and Therapy 10.3390/molecules25153531 2020
p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells 10.1074/jbc.ra118.004671 2019
Loss of the p53 transactivation domain results in high amyloid aggregation of the -40p53 isoform in endometrial carcinoma cells 10.1074/jbc.ra119.007566 2019
Evaluation of neuroprotective activity of digoxin and semisynthetic derivatives against partial chemical ischemia 10.1002/jcb.28971 2019
Evaluation Of The Effect Of Cafeteria Diet In The Kidney Na,K-ATPase Activity And Oxidative Stress 10.1002/jcb.29228 2019
RNA modulates aggregation of the recombinant mammalian prion protein by direct interaction 10.1038/s41598-019-48883-x 2019
Resveratrol prevents p53 aggregation in vitro and in breast cancer cells 10.18632/oncotarget.25631 2018
Balance between S-nitrosylation and denitrosylation modulates myoblast proliferation independently of soluble guanylyl cyclase activation 10.1152/ajpcell.00140.2016 2017
Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain 10.1074/jbc.m116.762096 2017
Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease? 10.1101/cshperspect.a023614 2016
Prion protein-coated magnetic beads: Synthesis, characterization and development of a new ligands screening method 10.1016/j.chroma.2014.12.014 2015
Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer 10.3389/fonc.2015.00097 2015
The aggregation of mutant p53 produces prion-like properties in cancer 10.4161/pri.27776 2014
Prion-like aggregation of mutant p53 in cancer 10.1016/j.tibs.2014.04.001 2014
Biophysical and morphological studies on the dual interaction of non-octarepeat prion protein peptides with copper and nucleic acids 10.1007/s00775-014-1115-8 2014
Expanding the Prion Concept to Cancer Biology: Dominant-Negative Effect of Aggregates of Mutant p53 Tumor Suppressor 10.1042/bsr20130065 2013
New structure-activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity 2013
Putative role of an ABC transporter in Fonsecaea pedrosoi multidrug resistance 10.1016/j.ijantimicag.2012.07.010 2012
Mutant p53 Aggregates into Prion-like Amyloid Oligomers and Fibrils: IMPLICATIONS FOR CANCER 10.1074/jbc.M112.340638 2012
Oroidin Inhibits the Activity of the Multidrug Resistance Target Pdr5p from Yeast Plasma Membranes 10.1021/np1006247 2011
Methoxy Stilbenes as Potent, Specific, Untransported, and Noncytotoxic Inhibitors of Breast Cancer Resistance Protein 10.1021/cb200435y 2011
Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion 10.1016/j.ymeth.2010.12.002 2011
Inhibitory effects of gallic acid ester derivatives on Saccharomyces cerevisiae multidrug resistance protein Pdr5p 10.1111/j.1567-1364.2009.00603.x 2010
Isolation of two bioactive diterpenic acids from Copaifera glycycarpa oleoresin by high-speed counter-current chromatography 10.1002/pca.1229 2010
Effect of different extracts from the Brazilian Atlantic Forest on the Pdr5p ATPase activity 10.1590/S0102-695X2008000100008 2008
Eventos:

(0.00% eventos com DOI)

Titulo DOI Ano
Green Tea (Camellia sinensis) and Olive (Olea europaea L.) Leaf Extracts for Cancer Chemoprevention: The Tumor Suppressor p53 as a Potential Molecular Target (EACR23-0591) 2023
Mutant p53 promotes tumor progression through its transmission between tumor cells in a prion-like manner (EACR23-1290) 2023
PRIMA-1 inhibits amyloid aggregation of mutant p53 in cancer cells 2019
Vitamin K-derived compounds with promising effects against mutant p53 aggregation 2019
Resveratrol prevents p53 aggregation in vitro and in vivo 2019
Resveratrol prevents p53 aggregation in vitro and in vivo 2018
EFFECTS OF MICHAEL ACCEPTORS COMPOUNDS ON P53 AGGREGATION IN BREAST AND OVARIAN CANCER CELLS 2018
ADVANCES ON THE STUDY OF P53 AGGREGATION USING ANTI-AMYLOID COMPOUNDS 2017
RESVERATROL PREVENTS p53 AGGREGATION IN VITRO AND IN BREAST CANCER CELLS 2017
Effects of Prima-1 and Michael Aceptors on Mutant p53 Aggregation 2017
ON THE SEARCH FOR MUTANT P53 ACTIVATORS ON HEPATOCELLULAR CARCINOMA 2017
EMPLOYING ANTI-AMYLOID COMPOUNDS FOR UNDERSTANDING OF THE AGGREGATION OF TUMOR SUPPRESSOR PROTEIN P53 2017
EFFECTS OF PRIMA-1 AND MICHAEL ACEPTORS ON MUTANT P53 AGGREGATION 2017
Resveratrol prevents p53 agregation in vitro and in breast cancer cells 2017
The p53 anti-aggregation effect of PRIMA-1 2017
PRIMA-1 REACTIVATES MUTANT P53 THROUGH THE MOBILIZATION OF ITS AGGREGATED FRACTION IN THE CELL 2016
THE ROLE OF CHAPERONES ON MUTANT P53 AGGREGATION 2016
RESVERATROL AND ITS STRUCTURAL ANALOGUES AS POTENTIAL INHIBITORS OF P53 PROTEIN AGGREGATION 2016
P53 AGGREGATION IN HEPATOCELLULAR CARCINOMA CELL LINES 2016
BIOCHEMICAL AND BIOPHYSICAL STUDIES OF THE INTERACTION BETWEEN HEPATITIS C VIRUS CORE PROTEIN AND P53 2016
Anti-amyloid compounds as new p53 aggregation inhibitors and cell sensitizers to cancer chemotherapy 2015
RNA-seq analysis reveals the relevance of ribosomal RNAs to Induce Recombinant Mouse Prion Protein Aggregation and Toxicity in vitro 2015
STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE HEPATITIS C VIRUS CORE PROTEIN AND ITS INTERACTION WITH THE TUMOR SUPRESSOR PROTEIN p53 2015
The p53 reactivator PRIMA-1 inhibits p53 aggregation 2015
POTENTIAL ROLE OF RESVERATROL AND ITS STRUCTURAL ANALOGS IN PREVENTING p53 TUMOR SUPPRESSOR PROTEIN AGGREGATION 2015
Understanding the p53 Aggregation Process through its Activators Resveratrol and PRIMA-1 2015
p53 Aggregation and prionoid effect and the modulation of this process by PRIMA-1 and its active metabolite, 2-methylene-3-quinuclidinone hydrate 2014
Resveratrol prevents p53 core domain aggregation 2014
The p53 reactivator PRIMA-1 inhibits p53 aggregation 2014
Does Resveratrol Prevent p53 Aggregation? 2014
A New Mechanism of Action for PRIMA-1 on p53 Reactivation 2013
Structural and Functional Analysis of the Hepatitis C Virus Core Protein 2013
Isolation and Characterization of RNA Molecules Bound to Recombinant Mouse Prion Protein 2013
The tumor suppressor protein p53 is structurally stabilized by a double-stranded DNA thioaptamer and protected from heat and high pressure denaturation 2012
Aggregation of mutant p53 into prion-like amyloid oligomers and fibrils?Implications for cancer 2012
Structural Stabilization of the Tumor Suppressor Protein p53 by a Double- Stranded DNA Thioaptamer 2012
Structural and Thermodynamic Characterization of the Capsid Protein of Hepatitis C Virus and its Interaction with the Tumor Suppressor Protein p53 2012
Estudo do Processo de Agregação da proteína p53 por Espectroscopia Raman 2012
Structural and Thermodynamic Characterization of the Capsid Protein of Hepatitis C Virus and its Interaction with the Tumor Suppressor Protein p53 2012
The tumor supressor protein p53 is protected from heat and high pressure denaturation by a double-stranded DNA thioaptamer 2012
Studies on the utilization of a thioaptamer for the rescue of p53 and its mutants 2011
Evaluation of the pathophysiological role of PrP:RNA interaction 2011
Effects of a thioaptamer on the rescue of p53 and its mutants 2011
Putative Role of an ABC transporter on Fonsecaea pedrosoi on Multidrug Resistance 2010
Study of the potential of Triterpens isolated from Lippia Lacunosa to inhibit rhodamine 6G efflux mediated by Pdr5p 2010
Cellular studies with PrP:RNA aggregates 2010
Studies on the utilization of a thioaptamer for the rescue of p53 and its R248Q mutant 2010
Structural and Physiological Aspects of PrP Interaction with RNA Molecules 2010
Effects of different groups of chalcones on ABCG2-overexpressing cells through mitoxantrone accumulation 2009
Oroidin: Activity on Pdr5p, a multidrug resistance protein from Saccharomyces cerevisiae 2009
CYTOTOXICITY OF N-PHENYL MALEIMIDES FOR MELANOMA AND LEUKEMIA CELL LINES AND INHIBITION OF MULTIDRUG RESISTENCE PROTEIN (Pdr5p) 2009
Study of triterpenes isolated from Lippia lacunosa as MDR inhibitors in fungal cells 2009
Análise por LC-PDA-MS e desreplicação de alcalóides bromopirrólicos da esponja Agelas sventres 2008
Compounds isolated from Stachytarpheta cayennensis as inhibitors of Rhodamine 6G efflux in Saccharomyces cerevisiae Pdr5p 2008
Cirsimaritin and a triterpen are potent inhibitors of Pdr5p activity 2008
Effect of marine sponge Agelas sventres on Saccharomyces cerevisiae multidrug resistance protein Pdr5p 2008
PLANT EXTRACTS USED IN BRAZILIAN TRADITIONAL MEDICINE: EFFECT ON PDR5P ATPASE ACTIVITY FROM SACCHAROMYCES CEREVISIAE 2007
EFFECT OF MARINE SPONGES PETROMICA CITRINA AND AGELAS SP.ON SACCHAROMYCES CEREVISIAE MULTIDRUG RESISTANCE PROTEIN PDR5P 2007
INHIBITORY EFFECTS OF GALLIC ACID ESTER DERIVATIVES ON SACCHAROMYCES CEREVISIAE MDR PROTEIN PDR5P 2007
IDENTIFICATION AND CHARACTERIZATION OF ABC TRANSPORTER HOMOLOGOUS TO PDR5P IN PARACOCCIDIOIDES BRASILIENSIS 2007
The effects of Cabralea canjerana ethanolic extract and its fractions on protein Pdr5p catalytic activity: searching for new multidrug resistance reversal agents 2006
Studies on Sacharomyces cerevisiae multidrug protein Pdr5p: inhibition by Lippia lacunosa and Lippia rotundifolia extracts 2006
Effect of marine sponges n Pdr5p catalytic activity of Saccharomyces cerevisae 2006
Efeito do extrato de Cabralea canjerana sobre a proteína Pdr5p 2005
Investigation of the modulatory effects of fractions obtained form the plant extracts of Mabea fistulifera and Bauhinia microstachya var. massambensis on ATPase activity of the yeast multidrug transporter Pdr5p 2005
Studies on yeast multidrug resistance protein Pdr5p: inhibition by Solanum gilo extracts 2005
Effect of Different Plant Extracts on Pdr5p 2004
Efeito de Fitoterápicos sobre a Atividade Enzimática da Pdr5p de Leveduras 2003
Stereochemistry of Lithium Enolates: Claisen-Aldol and Darzens Asymmetric Reactions 2003
Efeito de fitoterápicos sobre a atividade enzimática da Pdr5p de Leveduras 2003
Produção de Arilserinas via Condensação de Mukayama-Kobayashi 2002
Produção Enantiosseletiva de Alfa-amino ácidos: Alquilglicinas N,N-substituídas 2002
On The synthesis of New AntiHIV Compounds 2001
Síntese Assimétrica de Fenilserinas 2001
Preparação Diastereosseletiva de Epóxidos 2000
Perfil Químico e Farmacológico de Bromeliaceae Brasileira 1999
Publicações:
Minha Rede: